CX-516 Cortex Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 3, Issue 7, 2002, Pages 1081-1088

  Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,3 BENZODIOXOL 5 YLCARBONYL)PIPERIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; AMINO ACID RECEPTOR AFFECTING AGENT; AMPA RECEPTOR; AMPA RECEPTOR MODULATOR; AMPHETAMINE; ANIRACETAM; BDP 20; CLOZAPINE; CX 731; CYCLOTHIAZIDE; DESIPRAMINE; DIZOCILPINE; FARAMPATOR; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; ORG 24292; PLACEBO; PYRROLIDINE DERIVATIVE; RISPERIDONE; SPD 420; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; AREA UNDER THE CURVE; ATAXIA; ATTENTION DEFICIT DISORDER; AUTISM; BRAIN ELECTROPHYSIOLOGY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TOLERABILITY; DYSPHAGIA; EXCITATORY POSTSYNAPTIC POTENTIAL; FATIGUE; FINANCIAL MANAGEMENT; FORCED SWIMMING TEST; FRAGILE X SYNDROME; HEADACHE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPERTENSION; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; RNA SPLICING; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; TARDIVE DYSKINESIA; TOXICITY TESTING; TRANQUILIZING ACTIVITY; TREATMENT PLANNING;

ANIMALS; CLINICAL TRIALS; DIOXOLES; DRUG INDUSTRY; HUMANS; MENTAL DISORDERS; PIPERIDINES;

EID: 0036667175     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. 3135 Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Arai A, Lynch G Brain Res 1992 598 1-2 173-184
2. 225777 NIH to study Cortex's Ampalex in Alzheimers patients. Cortex Pharm Inc Press Release 1996 November 14
3. 225928 Psychological effects of a drug that facilitates brain AMPA receptors. Lynch G, Kessler M, Rogers G, Ambros-Ingerson J, Granger R, Schehr RS Int Clin Psychopharmacol 1996 11 1 13-19 Report that CX-516 has a positive effect on the recall of nonsense syllables.
4. 234221 Enrollment begins in phase I/II trial of Cortex's AMPALEX in Alzheimers disease patients. Cortex Pharmaceuticals Inc Press Release 1997 February 17
5. 240054 Reduction of methamphetamine hyperactivity by AMPA receptor facilitation: Positive interaction with typical and atypical antipsychotics. Johnson SA, Larson J, Luu NT, Herbst TA, Rogers G, Lynch G Pharmacologist 1997 39 1 120
6. 248440 Facilitation of glutamate receptors enhances memory. Staubli U, Rogers G, Lynch G Proc Natl Acad Sci USA 1994 91 2 777-781
7. 251267 Annual Report 1996 - Cortex Pharma Inc. Cortex Pharmaceuticals Inc Annual Report 1996
8. Effects of a memory-enhancing drug on DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropioninc acid receptor currents and synaptic transmission in hippocampus. Arai A, Kessler M, Rogers G, Lynch G J Pharmacol Exp Ther 1996 278 2 627-638
9. 260653 Facilitation of olfactory learning by a modulator of AMPA receptors. Larson J, Lieu T, Petchpradub V, LeDuc B, Ngo H, Rogers GA, Lynch G J Neurosci 1995 15 12 8023-8030 CX-516 improves the formation of long-term memory in rats in odor discrimination.
10. 260654 Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. McCoy L, Cox C, Richfield EK Eur J Pharmacol 1996 318 1 41-45
11. 260655 Effects of a centrally active benzoylpyrrolidine drug on AMPA receptor kinetics. Arai A, Kessler M, Ambros Ingerson J, Quan A, Yigiter E, Rogers G, Lynch G Neuroscience 1996 75 2 573-585 Effects of CX-516 on the kinetic properties of AMPA receptors were studied.
12. 266240 Enhancement by an ampakine of memory encoding in humans. Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers GA, Schehr RS, Lynch G Exp Neurol 1997 146 2 553-559 CX-516 was tested for its positive effect on visual association, recognition of odors and acquisition of a visuospatial maze.
13. 269819 Effects of the AMPA receptor modulator CX614 synaptic responses and AMPA receptor kinetics. Arai A, Ly J, Kessler M, Hennegriff M, Rogers G, Lynch G Abstr Soc Neurosci 1997 23 Pt 2 Abs 478.9
14. 272227 Attenuation of excitotoxic damage by nanomolar levels of AMPAkines in long-term hippocampal slices. Bahr BA, Kawasaki BT, Quach C, Marrs C, Rogers G Abstr Soc Neurosci 1997 23 Pt 2 Abs 900.9
15. 280526 Memory enhancing effects and pharmacokinetics of the new AMPA receptor modulator CX 516 in aged healthy male subjects. Rost KL, Stephan K, Koeman MAC, Rogers G, Schehr R, Fuder H, Herrmann WM Naunyn Schmiedebergs Arch Pharmacol 1997 356 4 Suppl 1 R55
16. 298828 Ampakine antidepressant activity in two animal models of depression. Malatynska E, Rogers GA, Goldenberg R, Shuck C, Crites G, Lynch G, Marrs C, Knapp RJ Int Congr Pharmacol 1998 P 35.132
17. 301247 A profile of the behavioral changes produced by facilitation of AMPA-type glutamate receptors. Davis CM, Moskovitz B, Nguyen MA, Tran BB, Arai A, Lynch G, Granger R Psychopharmacology 1997 133 2 161-167
18. 301248 AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. Rogan MT, Staubli UV, Ledoux JE J Neurosci 1997 17 15 5928-5935
19. 309232 AMPA receptor desensitization modulates synaptic responses induced by repetitive afferent stimulation in hippocampal slices. Arai A, Lynch G Brain Res 1998 799 2 235-242
20. 309235 The waveform of synaptic transmission at hippocampal synapses is not determined by AMPA receptor desensitization. Arai A, Lynch G Brain Res 1998 799 2 230-234
21. 309242 GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: A reverse transcriptase-polymerase chain reaction (RT-PCR) study. Eastwood SL, Burnet PWJ, Harrison PJ Brain Res Mol Brain Res 1997 44 1 92-98
22. 309246 Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. Granger R, Deadwyler S, Davis M, Moskovitz B, Kessler M, Rogers G, Lynch G Synapse 1996 22 4 332-337
23. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Granger R, Staubli U, Davies M, Perez Y, Nilsson L, Rogers GA, Lynch G Synapse 1993 15 4 326-329
24. 309260 Facilitative effets of the ampakine CX516 on short-term memory in rats: Enhacement of delayed-nonmatch-to-sample performance. Hampson RE, Rogers G, Lynch G, Deadwyler SA J Neurosci 1998 18 7 2740-2747
25. 309261 AMPA receptor binding and subunit mRNA expression in prefrontal cortex an striatum of elderly schizophrenics. Healy DJ, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ, Meador-Woodruff JH Neuropsychopharmacology 1998 19 4 278-286
26. 309264 Stable expression of recombinant AMPA receptor subunits: Binding affinities and effects of allosteric modulators. Hennegriff M, Arai A, Kessler M, Vanderklish P, Mutneja MS, Rogers G, Neve RL, Lynch G J Neurochem 1997 68 6 2424-2434
27. 309267 Regional preferences of AMPA receptor modulators determined through agonist binding autoradiography. Kessler M, Mutneja MS, Rogers G, Lynch G Brain Res 1998 783 1 121-126
28. 309278 Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Lynch G, Granger R, Ambros-Ingerson J, Davis CM, Kessler M, Schehr R Exp Neurol 1997 145 1 89-92
29. 309286 Enhanced glutamatergic neurotransmission facilitates classical conditioning in the freely moving rat. Shors TJ, Servatius RJ, Thompson RF, Rogers G, Lynch G Neurosci Lett 1995 186 2-3 153-156
30. 309289 Effects of pharmacologically facilitating glutamatergic transmission in the trisynaptic intrahippocampal circuit. Sirvio J, Larson J, Quach CN, Rogers GA, Lynch G Neuroscience 1996 74 4 1025-1035
31. 309316 Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Staubli U, Perez Y, Xu FB, Rogers G, Ingvar M, Stoneelander S, Lynch G Proc Natl Acad Sci USA 1994 91 23 11158-11162
32. 309338 Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Vanover KE J Pharmacol 1997 332 2 115-119
33. 309354 AMPA receptor activation potentiated by the AMPA modulator 1-BCP is toxic to cultured rat hippocampal neurons. Yamada KA Neurosci Lett 1998 249 2-3 119-122
34. 309355 Modulating excitatory synaptic neurotransmission: Potential treatment for neurological disease? Yamada KA Neurobiol Dis 1998 5 2 67-80 Review discussing the concept of positive modulation of AMPA receptors in relation to cognitive and neurotoxic effects.
35. 310943 Excitatory Amino Acids 'Ten Years Later' (Part II) Selected Presentations Relevant for Drug Development, Manaus, Brazil. IDDB Meeting Report 1998 November 18-22
36. 325719 Cortex receives National Institutes of Health small business grant; AMPAkines investigated as a potential new therapy for stroke. Cortex Pharmaceuticals Inc Press Release 1999 May 24
37. 352775 Cortex Pharmaceuticals' AMPAKINESs increase neurotrophin expression - Increased neurotrophic factors may slow or possibly stop the normal brain ageing process. Cortex Pharmaceuticals Inc Press Release 2000 January 18
38. 363618 Shire and Cortex announce agreement to evaluate AMPAKINE CX516 for the treatment of attention deficit hyperactivity disorder (ADHD). Shire Pharmaceuticals Group Plc Press Release 2000 April 19 CX-516, licensed to Shire, appears to be covered by the PCT application WO-09638414, which has been filed in 81 countries and granted in the US. The compound is stated to be useful in the treatment of a range of neurological disorders, including schizophrenia and depression.
39. 371936 Synergistic interactions between AMPAkines and antipsychotic drugs. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A, Rogers GA, Lynch G J Pharmacol Exp Ther 1999 289 1 392-397
40. 385846 Cortex announces collaborative research, joint clinical research and licensing agreements. Cortex Pharmaceuticals Inc Press Release 2000 October 16
41. 388709 Society for Neuroscience 30th Annual Meeting (Part IV) - Overnight Report - New Orleans, LA, USA. Nicholls R IDDB Meeting Report 2000 November 4-9
42. 397366 Organon exercises option to license Cortex AMPAKINE technology for depression. Cortex Pharmaceuticals Inc Press Release 2001
43. 412513 Shire Pharmaceuticals to initiate trial of AMPAKINE CX516 in patients with attention deficit hyperactivity disorder (ADHD). Shire Pharmaceuticals Group Plc Press Release 2001 June 13
44. 417935 Novel AMPA receptor potentiators LY392098 and LY404187: Effects on recombinant human AMPA receptors in vitro. Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, Zarrinmayeh H, Ho K, Peters D, Grabell J, Gupta A, Zimmerman DM, Bleakman D Neuropharmacology 2001 40 8 976-983
45. 417944 Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. Vandergriff J, Huff K, Bond A, Lodge D Neuropharmacology 2001 40 8 1003-1009
46. 426041 A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G J Clin Psychopharmacol 2001 21 5 484-487
47. 428263 Differential effects of AMPA receptor modulators on synaptic plasticity. Xia YF, Kessler M, Arai AC Abstr Soc Neurosci 2001 27 Abs 610.14
48. 441275 Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. Lauterborn JC, Lynch G, VAnderklish P, Arai A, Gall CM J Neurosci 2000 20 1 8-21
49. 441315 AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN Neurology 2000 54 8 1589-1595
50. 444442 Survival signaling and selective neuroprotection through glutamatergic transmission. Bahr BA, Bendiske J, Brown QB, Munirathinam S, Caba E, Rudin M, Urwyler S, Sauter A, Rogers G Exp Neurol 2002 174 1 37-47
51. 450134 Drug development pipeline: CX-546, CX-614, CX-729, CX-815, Org-24448, CX-516. Cortex Pharmaceuticals Inc Company Communication 2002 May 02
52. 450460 Differential modulation of the GYKI 53784-induced inhibition of AMPA currents by various AMPA-positive modulators in cerebellar Purkinje cells. Kapus G, Bodi I, Pataki G, Gueritaud JP, Szekely JI, Tarnawa I Eur J Pharmacol 2000 397 1 43-47
53. 450497 Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Knapp RJ, Goldenberg R,Shuck C, Cecil A, Watkins J, Miller C, Crites G, Malatynska E Eur J Pharmacol 2002 440 1 27-35
54. 450499 Effect of AMPA receptor modulators on hippocampal and cortical function. Black MD, Wotanis J, Schilp DE, Hanak SE, Sorensen SM, Wettstein JG Eur J Pharmacol 2000 394 1 85-90
55. 450501 Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG Proc Natl Acad Sci USA 2001 98 20 11047-11054
56. 450503 Positive modulators of AMPA receptors as a potential treatment of schizophrenia. Danysz W Curr Opin Invest Drugs 2002 3 7
57. 450506 Positive modulation of hippocampal AMPA receptors promotes recovery several hours after trimethyltin-induced excitotoxicity. Munirathiam S, Gerald M, Bahr BA Soc Neurosci Abst 2000 26 Abs 183.15
58. 450516 The AMPAKINE CX-516 increasese 5-HT release in frontal cortex of freely moving rats in vivo. Ge J, Hill D, Boxall A, Shahid M Soc Neurosci Abst 2001 27 Abs 701.7
59. 450519 Treatment of Alzheimer's disease with CX516 (Ampalex). INTERNET SITE www.clinicaltrials.gov 2002 May 07 Information on the NIH study investigating the use of CX-516 in patients with Alzheimer's disease.
60. 450522 Cortex receives broad patent covering combination therapies with AMPAkines(R) for treatment of schizophrenia. INTERNET SITE www.headlines.schizophrenianet.org 2001 January 24 Information regarding Harvard Medical School's small clinical trial of CX-516 in schizophrenic patients.